Loss of heterozygosity does not occur in BRCA1/2 mutant pediatric solid and central nervous system tumors.

MLA

Groves, Andrew, et al. “Loss of Heterozygosity Does Not Occur in BRCA1/2 Mutant Pediatric Solid and Central Nervous System Tumors.” Pediatric Blood & Cancer, vol. 70, no. 11, Nov. 2023, p. e30643. EBSCOhost, https://doi.org/10.1002/pbc.30643.

APA

Groves, A., Ward, A., Li, Y. Y., Lazo de la Vega, L., Nag, A., Forrest, S. J., Gupta, H. V., Thorner, A. R., Meyerson, M., Kamihara, J., Cherniack, A. D., & Janeway, K. A. (2023). Loss of heterozygosity does not occur in BRCA1/2 mutant pediatric solid and central nervous system tumors. Pediatric Blood & Cancer, 70(11), e30643. https://doi.org/10.1002/pbc.30643

Chicago

Groves, Andrew, Abigail Ward, Yvonne Y Li, Lorena Lazo de la Vega, Anwesha Nag, Suzanne J Forrest, Hersh V Gupta, et al. 2023. “Loss of Heterozygosity Does Not Occur in BRCA1/2 Mutant Pediatric Solid and Central Nervous System Tumors.” Pediatric Blood & Cancer 70 (11): e30643. doi:10.1002/pbc.30643.